Brief: Asklepion Pharmaceuticals Signs Contract To Utilize Netramark Technology In Phase III Pediatric Cardiac Study
05/08/2025 14:27
Aug 5 (Reuters) - NetraMark Holdings Inc AIAI.CD: ASKLEPION PHARMACEUTICALS SIGNS CONTRACT TO UTILIZE NETRAMARK TECHNOLOGY IN PHASE III PEDIATRIC CARDIAC STUDY Source text: ID:nGNXbDJmgz Further company coverage: AIAI.CD ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NetraMark Holdings
See all newsBrief: Netramark Announces Uplisting To Toronto Stock Exchange
Brief: Netramark Signs Four New Contracts With A Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights
Brief: Asklepion Pharmaceuticals Signs Contract To Utilize Netramark Technology In Phase III Pediatric Cardiac Study
Brief: NetraMark Holdings Signs Contract With AlgoTx To Enhance Clinical Trial Design For ATX01
Brief: Netramark And Worldwide Clinical Trials Announce Agreement To Transform Clinical Trial Design With Ai-Powered Precision